The future leaves
signals in time.

Nature Biotechnology published an item titled "Genome editing." The available information contains only the headline, with no further details on methods or findings.

Nature Biotechnology published an item tracing the origins of the CRISPR–Cas system; the available context provides no further details about its content.

A Nature Biotechnology headline describes RevMed's pancreatic cancer drug as a "first", but no further details are provided in the available context, so the specific achievement remains unclear.

A Nature Medicine headline describes a health-system-scale, episode-resolved multimodal atlas of cancer cachexia. No further details are provided in the available context, so the study's methods and findings remain unclear.

Scientists have developed a mathematical model showing how common metals such as copper and zinc may influence the buildup of proteins associated with Alzheimer's disease, while exploring possible ways to stop the process. The findings could help researchers identify strategies for preventing harmful plaque formation; this remains model-stage work, not demonstrated human efficacy.

Scientists have discovered a hidden cleanup system at the back of the eye that drains fluid and waste through a previously unknown pathway. The finding, demonstrated in mice, could open the door to new treatments for glaucoma, macular degeneration, and other causes of blindness.

Texas A&M researchers found that polyethylene microplastics, a widely used plastic previously considered relatively harmless, may contribute to fatty liver disease, with potentially worse effects when combined with an unhealthy diet.

In a year-long clinical trial, researchers found that adjusting foot angle while walking reduced osteoarthritis pain by an amount comparable to medication, without drugs or surgery. MRI scans also showed participants who adopted the personalized walking technique experienced slower deterioration in a marker of knee cartilage health.

In the NEOPRISM-CRC trial, 32 patients with stage two or three bowel cancer of a specific genetic form received pembrolizumab for up to nine weeks before surgery instead of usual post-surgery chemotherapy. After nearly three years of follow-up, none had experienced recurrence, including those with small traces of disease remaining.

WHO has announced the SCORE for Health Data Technical Package, a new approach intended to improve countries' access to timely, reliable, validated and comparable health data for COVID-19 response and beyond. The agency says many countries still lack the infrastructure to routinely gather health data and the analytical capacity to use it for effective health action and emergency response.

Researchers have uncovered a new way bacteria detect viral attacks: a virus-produced enzyme cuts a bacterial sensor protein, triggering a self-destructing immune response. The discovery could lead to more effective phage therapies against antibiotic-resistant bacteria and offers insight into ancient immune mechanisms shared with humans.

Scientists tested five natural compounds, including curcumin and berberine, on cancer cells and healthy muscle cells. All disrupted cancer cell energy production and pushed many cells into a non-dividing state, with curcumin showing the strongest overall effect and a relatively favorable safety profile, while some other compounds caused more toxicity. This is cell-level research.

An AI-assisted scoping review examining code sharing in clinical prediction model research appears via Nature Medicine. The feed supplies no methods, scope, or findings, so no results can be reported here.

Nature Medicine published an addendum concerning aberrant epithelial GREM1 expression initiating colonic tumorigenesis from cells outside the stem cell niche. No further details were provided beyond the headline, so the specific findings cannot be confirmed.

Researchers report encouraging findings from the first clinical cohort of blind people treated with optogenetic therapy, which the report says shows promise for vision restoration. Specific efficacy details are not provided in the available context.

Argenx said its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder. The late-stage study failure is described as an unusual setback for the company.

Yale researchers report that in preclinical studies, the FDA-approved epilepsy drug lacosamide appears to block a protein involved in both pain signaling and cartilage destruction, potentially helping damaged joints shift back toward repair. The findings are preclinical and not yet confirmed in humans.